New CMO joins Khondrion

Former Kinesis Director Clinical Development Edwin Spaans appointed as Khondrion’s Chief Medical Officer. NIJMEGEN –December 15, 2014 ‐ Khondrion, The Netherlands based biopharmaceutical company developing a treatment for mitochondrial disease, announced today...

FDA Orphan Drug Designation

Published: 25 November 2014 Khondrion has received an Orphan Drug Designation from the FDA of its frontrunner compound KH176, in the treatment of inherited mitochondrial respiratory chain diseases. Find more articles BIO-Europe 2018: Interview with Mike Ward, Chief...